RT Journal Article
SR Electronic
T1 Biochemical, Biophysical, and Immunological Characterization of Respiratory Secretions in Severe SARS-CoV-2 (COVID-19) Infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.28.22272848
DO 10.1101/2022.03.28.22272848
A1 Michael J. Kratochvil
A1 Gernot Kaber
A1 Sally Demirdjian
A1 Pamela C. Cai
A1 Elizabeth B. Burgener
A1 Nadine Nagy
A1 Graham L. Barlow
A1 Medeea Popescu
A1 Mark R. Nicolls
A1 Michael G. Ozawa
A1 Donald P. Regula
A1 Ana E. Pacheco-Navarro
A1 Samuel Yang
A1 Vinicio A. de Jesus Perez
A1 Harry Karmouty-Quintana
A1 Andrew M. Peters
A1 Bihong Zhao
A1 Maximilian L. Buja
A1 Pamela Y. Johnson
A1 Robert B. Vernon
A1 Thomas N. Wight
A1 Stanford COVID-19 Biobank Study Group
A1 Carlos E. Milla
A1 Angela J. Rogers
A1 Andrew J. Spakowitz
A1 Sarah C. Heilshorn
A1 Paul L. Bollyky
YR 2022
UL http://medrxiv.org/content/early/2022/04/04/2022.03.28.22272848.abstract
AB Thick, viscous respiratory secretions are a major pathogenic feature of COVID-19 disease, but the composition and physical properties of these secretions are poorly understood. We characterized the composition and rheological properties (i.e. resistance to flow) of respiratory secretions collected from intubated COVID-19 patients. We find the percent solids and protein content are greatly elevated in COVID-19 compared to heathy control samples and closely resemble levels seen in cystic fibrosis, a genetic disease known for thick, tenacious respiratory secretions. DNA and hyaluronan (HA) are major components of respiratory secretions in COVID-19 and are likewise abundant in cadaveric lung tissues from these patients. COVID-19 secretions exhibit heterogeneous rheological behaviors with thicker samples showing increased sensitivity to DNase and hyaluronidase treatment. In histologic sections from these same patients, we observe increased accumulation of HA and the hyaladherin versican but reduced tumor necrosis factor–stimulated gene-6 (TSG6) staining, consistent with the inflammatory nature of these secretions. Finally, we observed diminished type I interferon and enhanced inflammatory cytokines in these secretions. Overall, our studies indicate that increases in HA and DNA in COVID-19 respiratory secretion samples correlate with enhanced inflammatory burden and suggest that DNA and HA may be viable therapeutic targets in COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research program is supported by a grant from the Stanford Innovative Medicines Accelerator program and the COVID-19 Response program from Stanford ChEM-H (Chemistry, Engineering & Medicine for Human Health). The Stanford COVID-19 Biobank Study Group and A.J.R. are funded by NIH/ NHLBI K23 HL125663. A.J.R. was supported by NIH grant T32 AI007502-23.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All secretion samples were obtained under the auspices of research protocols approved the Stanford Institutional Review Board (IRB) (Stanford IRB approval #28205, #53685, #55650, #37232, and #43805). Samples were collected after written informed consent from patients or their surrogates prior to inclusion in the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.